Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for extended EYLEA HD dosing intervals for wet age-related macular degeneration and diabetic macular edema. The updated label allows ...

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related ...

REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.

Regeneron Pharmaceuticals has won Food and Drug Administration approval of extended dosing intervals of up to every 20 weeks for its Eylea HD eye drug.

Despite Regeneron’s impressive high-dose Eylea data, its high-stakes launch is delayed thanks to an unexpected FDA rejection. The FDA turned down the closely watched eye med because of manufacturing ...

The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...

For Regeneron, seven weeks can’t come soon enough. That’s when its longer-acting version of macular degeneration drug Eylea is up for a potential FDA approval. Until then however, Regeneron and ...

The US Food and Drug Administration has approved the extension of dosing intervals for Regeneron’s EYLEA HD (aflibercept) up ...

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...

When discussing how long Eylea stays in your system, it’s important to distinguish between how long the drug remains in your eye versus your bloodstream. According to the drug’s prescribing ...

Only a month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto the market. Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the ...